New Hope for PKD Patients: IMPEDE-PKD Research Study
A ground-breaking research study is underway to investigate whether the diabetes drug metformin can slow the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Understanding ADPKD: A Leading Cause of Kidney Failure
Marked by the growth of fluid-filled cysts in the kidneys, ADPKD is the 4th leading cause of kidney failure, with over 70% of those affected requiring kidney replacement therapy by age 58 (UK RaDaR data). With limited treatment options currently available, finding ways to slow cyst growth early is crucial to preventing irreversible kidney damage.
Metformin’s Potential to Slow Cyst Growth
Metformin, commonly used to treat diabetes, has shown promise in initial studies by potentially blocking signals that drive cyst growth. Recent clinical trials have also confirmed that metformin is safe for use in ADPKD patients.
The IMPEDE-PKD Study: A Global Effort
The IMPEDE-PKD trial will involve 1,174 participants from the UK, USA, Australia, and New Zealand, with 300 patients being recruited from the UK.
How the Study Will Be Conducted
In the first phase of the study, all participants will be gradually adjusted to an optimal metformin dosage. Afterwards, they will continue taking either metformin or a placebo for two years. Kidney function, pain levels, and quality of life will be closely monitored. As a double-blind trial, neither participants nor researchers will know who is receiving the medication or the placebo.
Aiming to Transform ADPKD Treatment
The study’s goal is to assess whether metformin can delay the progression of kidney disease and reduce the need for kidney replacement therapy. If successful, this research could transform the treatment landscape for those living with ADPKD.
For those interested in the study’s progress or in participating, stay tuned for additional information in the coming months.
Medical Illustration: Aimee Hutchinson
ADPKD, Research, PKD, PKDTreatment
- Hits: 675